Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18655547 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL18655564 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL18655562 | 0.87 | ALDH1A1 (0.35) | SMN1; SMN2LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL14630596 | 0.84 | ALDH1A1 (0.37) | SMN1; SMN2LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL18660429 | 0.81 | CTSK (0.35) | SMN1; SMN2LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL18660465 | 0.81 | CTSK (0.35) | SMN1; SMN2LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL18660631 | 0.81 | CTSK (0.35) | SMN1; SMN2LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL10650039 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL18655550 | 0.75 | TSHR (0.37) | SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL18655559 | 0.75 | TSHR (0.37) | SMN1; SMN2CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630917-B2 | Cysteamine prodrugs, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630917-B2 | Cysteamine prodrugs, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-04-25 | — | — | US | disclosed |
| US-20170081279-A1 | CYSTEAMINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081279-A1 | CYSTEAMINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081279-A1 | CYSTEAMINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | GLS, GLS2, CTH | SMN1; SMN2 1996/4885LMNA 2754/4885ALDH1A1 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.